At GT Biopharma, Inc., we are developing innovative drugs for the treatment of cancers and central nervous system diseases.
Quote | GT Biopharma Inc. (OTCMKTS:GTBP)
Last: | $0.50 |
---|---|
Change Percent: | 13.64% |
Open: | $0.43 |
Close: | $0.50 |
High: | $0.5 |
Low: | $0.42 |
Volume: | 788,756 |
Last Trade Date Time: | 02/10/2021 04:54:28 pm |
News | GT Biopharma Inc. (OTCMKTS:GTBP)
IND clearance for GTB-3650, a 2 nd generation nanobody TriKE ® for treatment of CD33+ leukemia expected in Q2 2024 Phase 1 trial initiation with GTB-3650 expected in 2H 2024 Anticipate IND submission for GTB-5550 TriKE ® for treatment ...
Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2 nd generation nanobody TriKE ® for treatment of CD33+ leukemia Phase 1 trial with GTB-3650 anticipated to start in 2H 2024 Anticipate submitting an IND for GTB-5550 target...
Message Board Posts | GT Biopharma Inc. (OTCMKTS:GTBP)
Subject | By | Source | When |
---|---|---|---|
Lets go! | So des ne | investorshub | 01/21/2023 9:37:23 PM |
There is something seriously wrong in this company. | conix | investorshub | 04/10/2022 1:23:34 AM |
GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid | conix | investorshub | 12/08/2021 2:53:00 PM |
Was the CEO and CFO fired for cause? | conix | investorshub | 12/05/2021 5:23:21 PM |
I think the general biotech atmosphere is mostly | Plummy Potter | investorshub | 12/05/2021 2:44:54 PM |
News, Short Squeeze, Breakout and More Instantly...
IND clearance for GTB-3650, a 2 nd generation nanobody TriKE ® for treatment of CD33+ leukemia expected in Q2 2024 Phase 1 trial initiation with GTB-3650 expected in 2H 2024 Anticipate IND submission for GTB-5550 TriKE ® for treatment ...
Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2 nd generation nanobody TriKE ® for treatment of CD33+ leukemia Phase 1 trial with GTB-3650 anticipated to start in 2H 2024 Anticipate submitting an IND for GTB-5550 target...
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adj...